Venus Medtech (Hangzhou) Inc.

Informe acción SEHK:2500

Capitalización de mercado: HK$2.5b

Venus Medtech (Hangzhou) Dirección

Dirección controles de criterios 1/4

El CEO de Venus Medtech (Hangzhou)'s es Lin Haosheng Lim , nombrado en Dec 2016, tiene una permanencia de 7.17 años. compensación anual total es CN¥1.26M, compuesta por 85.4% salario y 14.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.72% de las acciones de la empresa, por valor de HK$17.67M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 2.9 años, respectivamente.

Información clave

Lin Haosheng Lim

Chief Executive Officer (CEO)

CN¥1.3m

Compensación total

Porcentaje del salario del CEO85.4%
Permanencia del CEO7.2yrs
Participación del CEO0.7%
Permanencia media de la dirección1.9yrs
Promedio de permanencia en la Junta Directiva2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

May 29
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

May 11
What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07
Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12
Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04
Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28
We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09
Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01
Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16
We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12
A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05
Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07
Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14
What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29
Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29
Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08
Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lin Haosheng Lim en comparación con los beneficios de Venus Medtech (Hangzhou)?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥1mCN¥1m

-CN¥1b

Sep 30 2022n/an/a

-CN¥759m

Jun 30 2022n/an/a

-CN¥461m

Mar 31 2022n/an/a

-CN¥417m

Dec 31 2021CN¥1mCN¥694k

-CN¥374m

Compensación vs. Mercado: La compensación total de Lin Haosheng($USD175.50K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD394.47K).

Compensación vs. Ingresos: La compensación de Lin Haosheng ha aumentado mientras la empresa no es rentable.


CEO

Lin Haosheng Lim (49 yo)

7.2yrs

Permanencia

CN¥1,263,000

Compensación

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Hou-Sen Lim
GM, COO & CTO7.2yrsCN¥1.26m0.72%
CN¥ 17.7m
Fei Wang
Chief Financial Officerless than a yearsin datossin datos
Joyce Heo
Director of Sales1.9yrssin datossin datos
Christopher Richardson
Head of U.S. Operations4.6yrssin datossin datos
Amir Gross
Head of Venus Global Heart Valve Innovation Center1.9yrssin datossin datos
Shakeel Osman
Senior Vice President of Sales Europe1.9yrssin datossin datos
Liu Meirong
Executive Director1.1yrssin datossin datos
Liqiao Ma
Executive Directorless than a yearsin datos0.0084%
CN¥ 208.0k
Wai Chiu Wong
Company Secretary3.1yrssin datossin datos

1.9yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2500 no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Liu Meirong
Executive Director1.1yrssin datossin datos
Liqiao Ma
Executive Directorless than a yearsin datos0.0084%
CN¥ 208.0k
Martin B. Leon
Member of Advisory Boardno datasin datossin datos
Chaim Lotan
Member of Global Advisory Board4.1yrssin datossin datos
Ting Yuk Wu
Independent Non-Executive Director5.3yrsCN¥423.00ksin datos
Chi Wai Suen
Independent Non-Executive Director4.6yrsCN¥335.00ksin datos
Wei Wang
Shareholders Representative Supervisor5.3yrssin datossin datos
Scott Lim
Member of Global Advisory Board4.1yrssin datossin datos
Min Shao
Employee Representative Supervisor1.5yrssin datossin datos
Zhang Ao
Non-Executive Director1.1yrssin datossin datos
Yue Li
Shareholders Representative Supervisor1.8yrssin datossin datos

2.9yrs

Permanencia media

48yo

Promedio de edad

Junta con experiencia: La junta directiva de 2500 no se considera experimentada (2.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.